March 2017 Newsletter
IASLC Lung Cancer News Enters Year Two
The first issue of volume two of the IASLC Lung Cancer News (ILCN) is now published and available for download on our website. This issue contains a wealth of material regarding the latest trends within the field of lung cancer treatment and care. From meeting highlights and overviews of on-going projects to analysis of drug development and perspectives from industry leaders, this issue of the ILCN is a must-read for anyone involved in the lung cancer community.
Read the ILCN online or download your own copy. The ILCN will be published six times in 2017.
The Second Edition of the IASLC Staging Manual/Handbook Rolls Out
The recently-released eighth edition of the TNM staging system is informed by a database comprised of 94,708 patients that were diagnosed around the world from 1999-2010. The objective was to further explore and analyze the impact on prognosis of tumor size and of the different T descriptors; the prognostic significance of tumor burden in hilar and mediastinal lymph nodes; and the confirmation of the revised M1 categories (M1a and M1b) of the seventh edition of the classification, along with the prognostic impact of number and anatomic location of metastases.
The Second Edition of the IASLC Staging Manual/Handbook in Thoracic Oncology reports on the latest revisions of the tumor, node and metastasis (TNM) classifications of thoracic malignancies, namely, lung cancer, malignant pleural mesothelioma, carcinoma of the esophagus and of the esophago-gastric junction, and thymic epithelial tumors.
The eighth edition of the TNM staging system has been officially accepted by the Union for International Cancer Control (UICC) and the American Joint Committee on Cancer (AJCC); however, the AJCC has delayed its implementation of the eighth edition of the staging system until 2018.
The Manual and the Handbook are now available for purchase on Amazon.com.
Squamous Lung Cancer Resource Center
We have compiled a variety of multi-media resources on our website for patients and caregivers contending with squamous lung cancer. These resources have been developed and reviewed by the Squamous Lung Cancer Consortium, a group of 25 global experts, along with nurses/nurse navigators and patient advocates.
The educational material is geared towards both patients and caregivers and includes videos, slide kits, key paper summaries and downloadable PDF booklets. Intended to be a source of information, education and support, these resources should not be seen as a substitute for consulting with a healthcare provider.
IASLC to be Represented at the Denver Colfax Marathon
The IASLC headquarters will take part in the Kaiser Permanente Colfax Marathon, held in May in Denver, Colorado. IASLC employees will be running to raise money for the IASLC Foundation, which funds our fellowship programs.
To support the IASLC Foundation, please visit our donation page.
Academic, Career and Funding Opportunities
As a service to our members, we post opportunities related to lung cancer and other thoracic malignancies on our website.
This now includes academic career opportunities. Click here to review post-doctoral and other career opportunities submitted to IASLC. If you have an academic career opportunity, please email it to firstname.lastname@example.org.
We also post opportunities when we receive information from grantors. We currently have four funding opportunities:
These opportunities are available to applicants from all countries. Click here to learn more.
Social Media Corner: Live Tweeting at Conferences
Dr. Sanjay Popat, Consultant Thoracic Medical Oncologist, The Royal Marsden Hospital, London, UK. @drsanjaypopat
From a professional viewpoint, the benefits of Twitter are huge and one of the most interesting aspects is “Live Tweeting” of scientific meetings. Here, a user will tweet during presentations attended so followers (usually non-attendees) can simultaneously see précise data with salient commentary. It is here that Twitter comes into its own. It is a platform able to instantaneously disseminate data, generate immediate opinion and capture impact. To followers, the experience is like attending a super-compact “best-of” talk, with instantaneous, open and lively discussion qualities often lacking after real presentations. It’s a great way to immediately track current issues, even if you’re at the meeting.
If you do decide to “Live Tweet” - fantastic! Welcome to the global community. Here are some tips. First, use the official hashtag of each meeting you attend, e.g. #BTOG2017. Most meetings will have one, and if not, check with organizers to make sure that Tweeting is allowed. Take photos of key slides or presenters; Twitter allows up to four per tweet, and be sure to add your comments. Plan your sessions, sit somewhere where your photos will be clear, and, if the speaker is on Twitter, tweet using their Twitter handle (@). If the topic being discussed impacts a specialist society, use their handle (e.g. @IASLC). Pair these with other relevant hashtags like #LCSM (Lung Cancer Social Media) or #mesothelioma to allow for easy compiling and searching.
Finally, never forget that whatever you Tweet is in the public domain forever, so please show respect. Most of all, enjoy the experience and add to the international debate. So, get signed up on Twitter; don’t be afraid. You needn’t immediately Tweet (yet); you can simply “lurk” and "follow" the many voices from the thoracic community.
March 2017: The IASLC and the Journal of Thoracic Oncology (JTO) are pleased to present the Editor's Choice each month to highlight certain articles of interest. The articles below from the March 2017 issue of the JTO are free for three months. Please share with your colleagues around the globe!
Alex A. Adjei, MD, PhD
HER2 Transmembrance Mutations (V659/G660) that Stablize Homo and Hetero-Dimerization are Rare Oncogenic Drivers in Lung Adenocarcinoma that Respond to Afatinib
Ou and colleagues have identified 15 cases of HER2 transmembrane domain mutations (HER2V659E/D, HER2G660D) through comprehensive genomic profiling (CGP) of 8551 lung adenocarcinomas. This represents 0.18% of the samples tested. Therapeutic responses to the pan-HER inhibitor, afatinib was documented in some of these tumors.
These findings have implications for the genomic analysis of NSCLC samples for therapeutic purposes. Consideration should be given to utilizing methods capable of detecting diverse HER2 alterations, including HER2 TMD mutations, in order to identify all patients who may benefit from HER2-targeted therapies. Dr. Ming Tsao and colleagues provide a thoughtful accompanying editorial.
Third generation EGFR TKIs have provided an important therapeutic option for patients with EGFR mutant NSCLC. However, as with all tyrosine kinase inhibitors, resistance invariably develops. Yang and colleagues describe acquired BRAF V600E mutation as a resistance mechanism to osimertinib treatment. These findings have obvious implications for the approach to the patient with secondary osimertinib resistance. Dr. Lecia Sequist and colleagues provide an insightful accompanying editorial.
Establishment of a Conditional Transgenic Mouse Model Recapitulating EML4-ALK-Positive Human Non-Small Cell Lung Cancer
Lim and colleagues describe the establishment of a conditional transgenic mouse model of EML4-ALK positive NSCLC, which should be an important resource for translational research.
Increasing Rates of No Treatment in Advanced Stage Non-Small Cell Lung Cancer Patients: A Propensity Matched Analysis
Using the U.S. National Cancer Database (NCDB) information from 1998 to 2012, David and colleagues demonstrated that the percentage of stage IIIA and IV patients who received no treatment increased over this period. This is an unanticipated result since novel, effective systemic therapies have become available over the past decade. With the advent of immunotherapy, a similar analysis that will focus on the period from 2012 to the present now has to be performed. It is hoped that the therapeutic nihilism that has been associated with lung cancer will start disappearing.
The following article was selected from the JTO by the IASLC Communications Committee to be promoted to the media and the public with a press release that was released at the time of online publication (Published Ahead of Print).
To read more IASLC press releases, please visit the IASLC Research Articles. These press releases are also announced via social media, so please follow the IASLC on Twitter, LinkedIn and Facebook to stay up to date on the latest scientific topics. Also, please follow the JTO on Twitter and Facebook.
East Asian female breast cancer patients receiving radiotherapy have a higher risk of developing second primary lung cancer.
All members whose memberships expired on December 31, 2016, will receive member renewal notices. If you chose a multi-year membership in 2016, your membership will continue uninterrupted.
The IASLC continued the three-year registration options for all categories (except complimentary Fellow Membership). Our three-year option "locks-in" the current membership rates. Regular members will save $150.00 over three years by selecting the three-year membership option ($600.00). Developing Country Members and Allied Health Professionals can avoid potential future increases and have the convenience of not having to renew each year.
We encourage all members to renew early to ensure that there is no interruption of benefits such as JTO delivery and online access. Please review the single-year and multi-year options available to you!
Thinking about joining the IASLC as a new member? Watch the video below to understand why IASLC is an organization like no other!
Lung Cancer Awareness Month Update: March 2017
To continue building on the momentum from the 2016 Lung Cancer Awareness Month (LCAM) harmonized strategy, the IASLC held a kickoff meeting in Santa Monica, California during the IASLC 17th Annual Targeted Therapies of the Treatment of Lung Cancer meeting.
During this meeting, the IASLC presented key metrics from the 2016 campaign. Throughout the month of November 30,000 people visited the official LCAM website, and the supporting digital advertising had a reach of over 18M impressions. The campaign's official Facebook page also accumulated nearly 39,000 fans.
The 2017 strategy will build on the successes from 2016, identifying key audiences and resources needed for building awareness with target audiences; improving website content and interactivity; allowing greater time for organizations and advocates to access materials and merchandise; and increasing diversity and scientific resources on the LCAM website.
There are numerous opportunities to expand the campaign in 2017, including forming partnerships with more cancer centers, hospital systems, medical societies and global advocates. Additionally, there is the opportunity to gain significantly more media coverage; advertise more robustly to patients, caregivers and providers; and include more scientific guides and resources on the LCAM website.
A special thanks to the LCAM 2016 supporters: Lilly Oncology, Merck & Co. and Helsinn, and to all of the LCAM 2016 and 2017 partners. If you wish to participate in 2017 Lung Cancer Awareness Month as an advocate, institution, organization partner or supporter, please contact Kristin.email@example.com.
2017 WCLC Advocacy Travel Award Application - NOW OPEN
Patient advocates and advocacy organizations can now apply for the International Association for the Study of Lung Cancer (IASLC) Patient Advocacy Travel Awards, which provide free registration and travel expenses stipends to up to five patient advocates for the IASLC 18th World Conference on Lung Cancer (WCLC) held October 15 - 18, 2016 in Yokohama, Japan.
The IASLC may award fewer than the maximum number of awards, depending on interest, applicant qualifications and the review process. Applicants for the Advocacy Travel Award are required to submit a detailed application, a summary of expected outcomes for attending the meeting and any other supporting documentation required for review by the IASLC. The award is open to organizations that can show 501(c)(3) or a similar type of non-profit status, and to individuals not affiliated with an advocacy organization.
Become a Member
Join the only international association solely dedicated to lung cancer research and treatment.
WCLC Virtual Library
February 20 - 23 2019Santa Monica, California
April 3 - 5 2019New York, New York
April 10 - 13 2019Geneva, Switzerland